Metabolic diseases, associated with abnormal processing of proteins, carbohydrates, and lipids, are the cause of significant morbidity and mortality. The orphan nuclear receptors, retinoic acid receptor-related orphan receptors 1, -2, and -3 (ROR1, ROR2, and ROR3), play important roles in regulating glucose and lipid metabolism, circadian rhythm, and have been implicated in the pathology of several diseases, including osteoporosis, autoimmune diseases, cancer, and obesity. Detailed examination of mice deficient in ROR1 has revealed a significant amount of information regarding its role in regulating metabolic pathways, including lipid metabolism. ROR3 has been extensively evaluated in regards to its essential role in Th17 cell development and association with certain autoimmune diseases. However, little is known about ROR3's role in other cell types or its mechanism of action. We have identified endogenous, functional ligands (7- oxygenated sterols) for ROR3. Additionally, we recently published that the benzenesulfoamide liver X receptor (LXR) agonist T0901317 is also a high affinity synthetic ligand for ROR3. 7-oxygenated sterols (71-hydroxycholesterol, 72- hydroxycholesterol, and 7-ketocholesterol) play important physiological and pathological roles in humans. The long-term objective is to determine the role of these ligands in regulating the activity of ROR3. We hypothesize that 7-oxygenated sterols are key ligands that regulate ROR3 mediated cellular processes. Our hypothesis will be tested in the following specific aims:
Specific Aim 1 will determine the specificity of ROR3 for various sterols;
Specific Aim 2 will determine the specificity of synthetic ligands on ROR3;and in Specific Aim 3 we will determine the effects of natural and synthetic ligands on ROR3 regulated physiological processes. These studies are essential for our understanding of how ligands may coordinate ROR3 regulated functions. Ligand-regulated nuclear hormone receptors have been definitively shown to be effective targets for the development of pharmaceuticals. We predict that these studies will provide the basis for novel therapeutics targeting ROR3 for the treatment of metabolic disorders.

Public Health Relevance

The orphan nuclear receptors, retinoic acid receptor-related orphan receptors 1, -2, and -3 (ROR1, ROR2, and ROR3), play important roles in regulating glucose and lipid metabolism, circadian rhythm, and have been implicated in the pathology of several diseases, including osteoporosis, autoimmune diseases, cancer, and obesity. We have identified endogenous functional ligands (7-oxygenated sterols) for ROR3 and while ROR3 has been extensively evaluated in regards to its role in Th17 cell development and association with certain autoimmune diseases, little is known about ROR3's role in other cell types or its mechanism of action. Ligand- regulated nuclear hormone receptors have been definitively shown to be effective targets for the development of pharmaceuticals and we predict that our proposed studies may provide the basis for novel therapeutics targeting ROR3 for treatment of metabolic diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32DK088499-02
Application #
8205652
Study Section
Special Emphasis Panel (ZDK1-GRB-W (O1))
Program Officer
Castle, Arthur
Project Start
2010-12-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
2
Fiscal Year
2012
Total Cost
$53,942
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Solt, Laura A; Burris, Thomas P (2015) Th17 cells in Type 1 diabetes: a future perspective. Diabetes Manag (Lond) 5:247-250
Solt, Laura A; Banerjee, Subhashis; Campbell, Sean et al. (2015) ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology 156:869-81
Matta-Camacho, Edna; Banerjee, Subhashis; Hughes, Travis S et al. (2014) Structure of REV-ERB? ligand-binding domain bound to a porphyrin antagonist. J Biol Chem 289:20054-66
Banerjee, Subhashis; Wang, Yongjun; Solt, Laura A et al. (2014) Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nat Commun 5:5759
Woldt, Estelle; Sebti, Yasmine; Solt, Laura A et al. (2013) Rev-erb-? modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 19:1039-46
Solt, Laura A; Kumar, Naresh; He, Yuanjun et al. (2012) Identification of a selective ROR? ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem Biol 7:1515-9
Solt, Laura A; Wang, Yongjun; Banerjee, Subhashis et al. (2012) Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485:62-8
Solt, Laura A; Kojetin, Douglas J; Burris, Thomas P (2011) The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Med Chem 3:623-38
Solt, Laura A; Kumar, Naresh; Nuhant, Philippe et al. (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472:491-4